Patient characteristics at baseline (modified intent to treat)
| . | Placebo . | Topiramate CR 175 mg/day . | Total . |
|---|---|---|---|
| n | 57 | 54 | 111 |
| Age (years) | 53.5 ± 11.1 | 51.8 ± 11.5 | 52.7 ± 11.3 |
| Male (%) | 42 | 22 | 32 |
| White (%) | 79 | 70 | 75 |
| Body weight (kg) | 110.2 ± 19.4 | 106.0 ± 17.2 | 108.1 ± 18.4 |
| BMI (kg/m2) | 37.7 ± 5.7 | 38.1 ± 5.3 | 37.9 ± 5.5 |
| Fasting plasma glucose (mmol/l) | 9.3 ± 2.0 | 9.2 ± 2.0 | 9.3 ± 2.0 |
| A1C (%) | 7.5 ± 0.82 | 7.6 ± 0.93 | 7.5 ± 0.87 |
| Baseline diabetes treatment (%) | |||
| Diet only | 30 | 22 | 26 |
| Diet and metformin | 70 | 78 | 74 |
| . | Placebo . | Topiramate CR 175 mg/day . | Total . |
|---|---|---|---|
| n | 57 | 54 | 111 |
| Age (years) | 53.5 ± 11.1 | 51.8 ± 11.5 | 52.7 ± 11.3 |
| Male (%) | 42 | 22 | 32 |
| White (%) | 79 | 70 | 75 |
| Body weight (kg) | 110.2 ± 19.4 | 106.0 ± 17.2 | 108.1 ± 18.4 |
| BMI (kg/m2) | 37.7 ± 5.7 | 38.1 ± 5.3 | 37.9 ± 5.5 |
| Fasting plasma glucose (mmol/l) | 9.3 ± 2.0 | 9.2 ± 2.0 | 9.3 ± 2.0 |
| A1C (%) | 7.5 ± 0.82 | 7.6 ± 0.93 | 7.5 ± 0.87 |
| Baseline diabetes treatment (%) | |||
| Diet only | 30 | 22 | 26 |
| Diet and metformin | 70 | 78 | 74 |
Data are means ± SD unless otherwise indicated.